Nicholas Murray

956 total citations
19 papers, 669 citations indexed

About

Nicholas Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nicholas Murray has authored 19 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Nicholas Murray's work include Myasthenia Gravis and Thymoma (3 papers), Immunotherapy and Immune Responses (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Nicholas Murray is often cited by papers focused on Myasthenia Gravis and Thymoma (3 papers), Immunotherapy and Immune Responses (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Nicholas Murray collaborates with scholars based in United Kingdom, Australia and United States. Nicholas Murray's co-authors include John Newsom–Davis, Angela Vincent, Bethan Lang, Dennis Wray, K. N., C. Bryce, Richard Klasa, Anthony W. Tolcher, Martin Gleave and Susan D’Aloisio and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Nicholas Murray

15 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicholas Murray United Kingdom 10 304 224 168 94 68 19 669
F. Cardenal Spain 11 222 0.7× 199 0.9× 337 2.0× 204 2.2× 43 0.6× 21 696
Hajime Yonezawa Japan 16 228 0.8× 203 0.9× 107 0.6× 106 1.1× 30 0.4× 60 753
James N. Gerson United States 10 374 1.2× 236 1.1× 123 0.7× 68 0.7× 107 1.6× 16 636
D Beck Switzerland 18 443 1.5× 323 1.4× 133 0.8× 66 0.7× 87 1.3× 24 726
Andrea Visentin Italy 20 195 0.6× 242 1.1× 206 1.2× 56 0.6× 322 4.7× 100 994
Kevin C. De Braganca United States 13 108 0.4× 272 1.2× 196 1.2× 152 1.6× 54 0.8× 34 613
Osarenoma Olomu United States 6 193 0.6× 257 1.1× 152 0.9× 183 1.9× 39 0.6× 17 663
Ruth Tatevossian United States 13 386 1.3× 442 2.0× 99 0.6× 131 1.4× 42 0.6× 29 1.0k
Bruce D. Cohen United States 10 160 0.5× 420 1.9× 322 1.9× 102 1.1× 57 0.8× 12 810
Angela J. Waanders United States 12 101 0.3× 214 1.0× 109 0.6× 101 1.1× 50 0.7× 45 481

Countries citing papers authored by Nicholas Murray

Since Specialization
Citations

This map shows the geographic impact of Nicholas Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Murray more than expected).

Fields of papers citing papers by Nicholas Murray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Murray. The network helps show where Nicholas Murray may publish in the future.

Co-authorship network of co-authors of Nicholas Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Murray. A scholar is included among the top collaborators of Nicholas Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Murray. Nicholas Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Dakle, Pushkar, Michelle Nguyen, Adele Barugahare, et al.. (2025). Notch dependent chromatin remodeling enables Gata3 binding and drives lineage specific CD8+ T cell function. Immunology and Cell Biology. 103(4). 365–382.
2.
3.
Murray, Nicholas, et al.. (2025). Clinical outcomes following implementation of an operative vaginal birth safety bundle: a prospective observational study and time-series analysis. American Journal of Obstetrics and Gynecology. 233(6). 670.e1–670.e18.
4.
Patrick, Ralph, Vaibhao Janbandhu, Vikram J. Tallapragada, et al.. (2024). Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies. Science Advances. 10(25). eadk8501–eadk8501. 22 indexed citations
5.
6.
Earl, Helena, Suet‐Feung Chin, Mark Dunning, et al.. (2013). Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy.. Journal of Clinical Oncology. 31(15_suppl). 1015–1015. 1 indexed citations
7.
8.
Earl, Helena, David Cameron, John M.S. Bartlett, et al.. (2012). ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS1144–TPS1144. 2 indexed citations
9.
James, Edward, Firouzeh Korangy, D. Boulanger, et al.. (2010). Differential Suppression of Tumor-Specific CD8+ T Cells by Regulatory T Cells. The Journal of Immunology. 185(9). 5048–5055. 17 indexed citations
10.
Chu, Quincy S., Mary Cianfrocca, Lori J. Goldstein, et al.. (2008). A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer. Clinical Cancer Research. 14(14). 4484–4490. 54 indexed citations
11.
Ng, Karl, Cindy Lin, Nicholas Murray, Andrew K. Burroughs, & Hugh Bostock. (2006). FC12.4 Conduction and excitability properties of nerves in end-stage liver disease. Clinical Neurophysiology. 117. 1–2. 1 indexed citations
12.
Chu, Quincy S., Laura H. Goldstein, Nicholas Murray, et al.. (2005). A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. Journal of Clinical Oncology. 23(16_suppl). 3001–3001. 22 indexed citations
13.
N., K., Martin Gleave, Richard Klasa, et al.. (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.. PubMed. 7(12). 3920–7. 156 indexed citations
14.
Bossy, David, Christopher D. Buckley, Claire Holness, et al.. (1995). Epitope mapping and functional properties of anti‐intercellular adhesion molecule‐3 (CD50) monoclonal antibodies. European Journal of Immunology. 25(2). 459–465. 27 indexed citations
15.
Arriagada, R., Noorie Choi, R. Feld, et al.. (1994). Combined modality therapy in small cell lung cancer. Lung Cancer. 10. S25–S28.
16.
Vincent, Angela, John Newsom–Davis, D. Wray, et al.. (1993). Clinical and Experimental Observations in Patients with Congenital Myasthenic Syndromesa. Annals of the New York Academy of Sciences. 681(1). 451–460. 20 indexed citations
17.
Newsom–Davis, John, Nicholas Murray, D. Wray, et al.. (1982). Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor.. PubMed. 5(9S). S17–20. 40 indexed citations
18.
Lang, Bethan, Dennis Wray, John Newsom–Davis, Angela Vincent, & Nicholas Murray. (1981). AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME. The Lancet. 318(8240). 224–226. 279 indexed citations
19.
Levitt, Mark L., et al.. (1978). Oat cell carcinoma of the lung: CNS metastases in spite of prophylactic brain irradiation.. PubMed. 62(1). 131–3. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Cardenal Breakdown of academic impact, for papers by Hajime Yonezawa Breakdown of academic impact, for papers by James N. Gerson Breakdown of academic impact, for papers by D Beck Breakdown of academic impact, for papers by Andrea Visentin Breakdown of academic impact, for papers by Kevin C. De Braganca Breakdown of academic impact, for papers by Osarenoma Olomu Breakdown of academic impact, for papers by Ruth Tatevossian Breakdown of academic impact, for papers by Bruce D. Cohen Breakdown of academic impact, for papers by Angela J. Waanders
Rankless by CCL
2026